Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
PMID: 39126895
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells. 2024 06 26; 13(13).
PMID: 38994959
Isolated vaginal recurrence in women with stage I endometrial cancer.
Isolated vaginal recurrence in women with stage I endometrial cancer. Gynecol Oncol. 2023 12; 179:9-15.
PMID: 37864854
An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study.
An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study. Acad Radiol. 2023 Jul; 30(7):1257-1269.
PMID: 36280517
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022 06 10; 40(17):1879-1891.
PMID: 35302882
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436.
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers (Basel). 2021 Feb 04; 13(4).
PMID: 33557446
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel). 2020 Aug 27; 12(9).
PMID: 32867127
Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.
Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy. Obstet Gynecol. 2020 03; 135(3):495-497.
PMID: 32028509